Biotech Stocks Under Scanner -- Geron, Keryx Biopharma, Heat Biologics, and ZIOPHARM Oncology

Thursday, December 1, 2016 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, December 1, 2016 /PRNewswire/ --

On Wednesday, November 30, 2016, the NASDAQ

Composite ended the trading session at 5,323.68, down 1.05%; the Dow Jones Industrial Average edged 0.01% higher, to finish at 19,123.58; and the S&P 500 closed at 2,198.81, down 0.27%. Losses were broad based as six out of nine sectors ended the
session in negative. This morning, has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Heat Biologics Inc. (NASDAQ: HTBX), and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Learn more about these stocks by downloading their free research reports in PDF format at:


Menlo Park, California-based Geron Corp.'s stock finished Wednesday's session 1.92% lower at $2.04 with a total volume of 1.08 million shares traded. Geron's shares have gained 10.27% in the past one month. Shares of the Company, which focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies, are trading below its 50-day and 200-day moving averages by 4.84% and 22.34%, respectively. Geron's stock has a Relative Strength Index (RSI) of 43.63. Sign up and read the free research report on GERN at:

Keryx Biopharma  

On Wednesday, shares in Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc. recorded a trading volume of 1.07 million shares. The stock ended the day 2.68% lower at $5.80. Keryx Biopharma's stock has gained 28.60% in the last one month, 41.46% in the previous three months, and 1.40% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 10.68% and 9.98%, respectively. Furthermore, shares of Keryx Biopharma, which focuses on providing therapies for patients with renal disease in the US, have an RSI of 52.29.

On November 9th, 2016, research firm Maxim Group upgraded the Company's stock rating from 'Hold' to 'Buy', issuing a target price of $7 per share. The complimentary research report on KERX can be downloaded at:

Heat Biologics  

Durham, North Carolina-based Heat Biologics Inc.'s stock fell 3.69%, to close the day at $2.87. The stock recorded a trading volume of 4.29 million shares, which was above its three months average volume of 1.49 million shares. Heat Biologics' shares have rallied 114.18% in the last one month and 103.55% in the previous three months. Shares of the Company, which focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the US, are trading 98.34% and 173.65% above its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 76.14. Register for free on and access the latest report on HTBX at:

ZIOPHARM Oncology  

On Wednesday, shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. ended the session 4.14% lower at $6.48 with a total volume of 1.97 million shares traded. ZIOPHARM Oncology's shares have gained 14.08% in the last one month and 27.81% in the previous three months. The stock is trading 10.23% above its 50-day moving average and 0.37% above its 200-day moving average. Moreover, shares of the Company, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have an RSI of 51.87. Get free access to your research report on ZIOP at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store